New Insights into Adiponectin and Leptin Roles in Chronic Kidney Disease
Susana Coimbra,
Susana Rocha,
Maria João Valente,
Cristina Catarino,
Elsa Bronze-da-Rocha,
Luís Belo,
Alice Santos-Silva
Affiliations
Susana Coimbra
TOXRUN—Toxicology Research Unit, University Institute of Health Sciences, Cooperativa de Ensino Superior Politécnico e Universitário (CESPU), CRL, 4585-116 Gandra, Portugal
Susana Rocha
Associate Laboratory i4HB-Institute for Health and Bioeconomy, Faculdade de Farmácia da Universidade do Porto, 4050-313 Porto, Portugal
Maria João Valente
Associate Laboratory i4HB-Institute for Health and Bioeconomy, Faculdade de Farmácia da Universidade do Porto, 4050-313 Porto, Portugal
Cristina Catarino
Associate Laboratory i4HB-Institute for Health and Bioeconomy, Faculdade de Farmácia da Universidade do Porto, 4050-313 Porto, Portugal
Elsa Bronze-da-Rocha
Associate Laboratory i4HB-Institute for Health and Bioeconomy, Faculdade de Farmácia da Universidade do Porto, 4050-313 Porto, Portugal
Luís Belo
Associate Laboratory i4HB-Institute for Health and Bioeconomy, Faculdade de Farmácia da Universidade do Porto, 4050-313 Porto, Portugal
Alice Santos-Silva
Associate Laboratory i4HB-Institute for Health and Bioeconomy, Faculdade de Farmácia da Universidade do Porto, 4050-313 Porto, Portugal
Chronic kidney disease (CKD) is commonly associated with a high burden of comorbidities and poor clinical outcomes. Malnutrition–inflammation–atherosclerosis syndrome is common in the more severe stages of CKD, suggesting a close interplay for these three comorbid conditions. Both malnutrition and obesity are associated with a disturbed adipokine profile and inflammation, contributing to a higher risk of cardiovascular disease (CVD) events. Adiponectin and leptin have important roles in carbohydrate and lipid metabolism, and in the inflammatory process. The effects of adiponectin and leptin alterations in CKD, which are usually increased, and their association with the different comorbidities found in CKD, will be focused on to understand their crosstalk with the risk of CVD events. Nonetheless, although adiponectin and leptin contribute to a higher risk of CVD events, further studies are warranted to fully clarify their roles, especially when different comorbidities exist.